NBIX logo

Neurocrine Biosciences, Inc. (NBIX) Free Cash Flow

Annual FCF:

$557.20M+$195.60M(+54.09%)
December 31, 2024

Summary

  • As of today, NBIX annual free cash flow is $557.20 million, with the most recent change of +$195.60 million (+54.09%) on December 31, 2024.
  • During the last 3 years, NBIX annual free cash flow has risen by +$324.10 million (+139.04%).
  • NBIX annual free cash flow is now at all-time high.

Performance

NBIX Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXcash flow metrics

Quarterly FCF:

$214.30M+$124.80M(+139.44%)
September 30, 2025

Summary

  • As of today, NBIX quarterly free cash flow is $214.30 million, with the most recent change of +$124.80 million (+139.44%) on September 30, 2025.
  • Over the past year, NBIX quarterly free cash flow has increased by +$64.40 million (+42.96%).
  • NBIX quarterly free cash flow is now -8.89% below its all-time high of $235.20 million, reached on December 31, 2024.

Performance

NBIX Quarterly Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXcash flow metrics

TTM FCF:

$593.10M+$64.40M(+12.18%)
September 30, 2025

Summary

  • As of today, NBIX TTM free cash flow is $593.10 million, with the most recent change of +$64.40 million (+12.18%) on September 30, 2025.
  • Over the past year, NBIX TTM free cash flow has increased by +$153.00 million (+34.76%).
  • NBIX TTM free cash flow is now -3.47% below its all-time high of $614.40 million, reached on March 31, 2024.

Performance

NBIX TTM Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXcash flow metrics

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

NBIX Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+54.1%+43.0%+34.8%
3Y3 Years+139.0%+113.2%+235.1%
5Y5 Years+321.2%+1297.2%+154.6%

NBIX Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+139.0%-8.9%+260.3%-3.5%+235.1%
5Y5-Yearat high+321.2%-8.9%+260.3%-3.5%+480.3%
All-TimeAll-Timeat high+463.9%-8.9%+260.3%-3.5%+410.3%

NBIX Free Cash Flow History

DateAnnualQuarterlyTTM
Sep 2025
-
$214.30M(+139.4%)
$593.10M(+12.2%)
Jun 2025
-
$89.50M(+65.4%)
$528.70M(+7.4%)
Mar 2025
-
$54.10M(-77.0%)
$492.20M(-11.7%)
Dec 2024
$557.20M(+54.1%)
$235.20M(+56.9%)
$557.20M(+26.6%)
Sep 2024
-
$149.90M(+182.8%)
$440.10M(-11.0%)
Jun 2024
-
$53.00M(-55.5%)
$494.60M(-19.5%)
Mar 2024
-
$119.10M(+0.8%)
$614.40M(+69.9%)
Dec 2023
$361.60M(+12.0%)
$118.10M(-42.2%)
$361.60M(-6.0%)
Sep 2023
-
$204.40M(+18.3%)
$384.70M(+37.0%)
Jun 2023
-
$172.80M(+229.2%)
$280.80M(+18.3%)
Mar 2023
-
-$133.70M(-194.7%)
$237.30M(-26.5%)
Dec 2022
$322.90M(+38.5%)
$141.20M(+40.5%)
$322.90M(+82.4%)
Sep 2022
-
$100.50M(-22.3%)
$177.00M(+33.5%)
Jun 2022
-
$129.30M(+368.8%)
$132.60M(+29.7%)
Mar 2022
-
-$48.10M(-923.4%)
$102.20M(-56.2%)
Dec 2021
$233.10M(+7.1%)
-$4.70M(-108.4%)
$233.10M(-27.7%)
Sep 2021
-
$56.10M(-43.3%)
$322.20M(+29.8%)
Jun 2021
-
$98.90M(+19.4%)
$248.20M(-5.8%)
Mar 2021
-
$82.80M(-1.9%)
$263.50M(+21.1%)
Dec 2020
$217.60M(+64.5%)
$84.40M(+571.5%)
$217.60M(-6.6%)
Sep 2020
-
-$17.90M(-115.7%)
$232.94M(-32.5%)
Jun 2020
-
$114.20M(+209.5%)
$345.12M(+18.7%)
Mar 2020
-
$36.90M(-63.0%)
$290.64M(+111.7%)
Dec 2019
$132.30M(+72.7%)
$99.74M(+5.8%)
$137.31M(+67.4%)
Sep 2019
-
$94.28M(+57.9%)
$82.01M(+85.2%)
Jun 2019
-
$59.71M(+151.3%)
$44.28M(>+9900.0%)
Mar 2019
-
-$116.43M(-362.0%)
$408.00K(-99.5%)
Dec 2018
$76.60M(+175.6%)
$44.44M(-21.4%)
$76.55M(+8.9%)
Sep 2018
-
$56.56M(+257.1%)
$70.31M(+4202.7%)
Jun 2018
-
$15.84M(+139.3%)
$1.63M(+102.6%)
Mar 2018
-
-$40.29M(-205.5%)
-$62.84M(+38.0%)
Dec 2017
-$101.27M(+8.2%)
$38.20M(+415.3%)
-$101.27M(+40.9%)
Sep 2017
-
-$12.11M(+75.1%)
-$171.44M(+10.3%)
Jun 2017
-
-$48.64M(+38.2%)
-$191.11M(-20.2%)
Mar 2017
-
-$78.72M(-146.2%)
-$159.06M(-44.2%)
Dec 2016
-$110.29M(-176.2%)
-$31.97M(-0.6%)
-$110.29M(-16.9%)
Sep 2016
-
-$31.79M(-91.7%)
-$94.35M(-15.8%)
Jun 2016
-
-$16.58M(+44.7%)
-$81.45M(-58.4%)
Mar 2016
-
-$29.95M(-86.8%)
-$51.42M(-28.8%)
Dec 2015
-$39.93M(+18.1%)
-$16.03M(+15.1%)
-$39.93M(-0.7%)
Sep 2015
-
-$18.89M(-240.4%)
-$39.65M(-19.7%)
Jun 2015
-
$13.45M(+172.9%)
-$33.13M(+42.1%)
Mar 2015
-
-$18.46M(-17.2%)
-$57.19M(-17.3%)
Dec 2014
-$48.75M(-61.7%)
-$15.75M(-27.3%)
-$48.75M(-10.6%)
Sep 2014
-
-$12.37M(-16.5%)
-$44.07M(-3.7%)
Jun 2014
-
-$10.61M(-5.9%)
-$42.52M(-1.2%)
Mar 2014
-
-$10.02M(+9.5%)
-$42.03M(-39.4%)
Dec 2013
-$30.15M(+16.9%)
-$11.07M(-2.4%)
-$30.15M(-7.6%)
Sep 2013
-
-$10.81M(-6.8%)
-$28.03M(-8.4%)
Jun 2013
-
-$10.12M(-646.4%)
-$25.86M(-13.4%)
Mar 2013
-
$1.85M(+120.7%)
-$22.80M(+37.1%)
Dec 2012
-$36.27M(-2404.5%)
-$8.95M(-3.6%)
-$36.27M(-122.3%)
Sep 2012
-
-$8.64M(-22.2%)
-$16.32M(-198.4%)
Jun 2012
-
-$7.07M(+39.1%)
-$5.47M(-111.8%)
Mar 2012
-
-$11.61M(-205.6%)
$46.21M(+3329.2%)
Dec 2011
-$1.45M(-102.9%)
$11.00M(+397.6%)
-$1.43M(+95.2%)
Sep 2011
-
$2.21M(-95.0%)
-$29.74M(-36.4%)
Jun 2011
-
$44.61M(+175.3%)
-$21.80M(-949.2%)
Mar 2011
-
-$59.25M(-242.2%)
$2.57M(-94.8%)
DateAnnualQuarterlyTTM
Dec 2010
$49.63M(+193.4%)
-$17.32M(-270.5%)
$49.63M(-6.3%)
Sep 2010
-
$10.15M(-85.3%)
$52.97M(+67.1%)
Jun 2010
-
$68.98M(+665.9%)
$31.70M(+162.3%)
Mar 2010
-
-$12.19M(+12.8%)
-$50.90M(+4.2%)
Dec 2009
-$53.13M(+29.6%)
-$13.97M(-25.8%)
-$53.13M(+4.4%)
Sep 2009
-
-$11.11M(+18.5%)
-$55.59M(+6.1%)
Jun 2009
-
-$13.63M(+5.4%)
-$59.21M(+3.7%)
Mar 2009
-
-$14.41M(+12.3%)
-$61.46M(+18.6%)
Dec 2008
-$75.49M(-25.9%)
-$16.44M(-11.6%)
-$75.50M(-19.0%)
Sep 2008
-
-$14.73M(+7.3%)
-$63.42M(+10.1%)
Jun 2008
-
-$15.88M(+44.2%)
-$70.51M(+4.1%)
Mar 2008
-
-$28.45M(-552.6%)
-$73.49M(-22.6%)
Dec 2007
-$59.96M(+41.5%)
-$4.36M(+80.0%)
-$59.96M(+17.3%)
Sep 2007
-
-$21.82M(-15.7%)
-$72.48M(+14.4%)
Jun 2007
-
-$18.86M(-26.4%)
-$84.69M(+12.0%)
Mar 2007
-
-$14.92M(+11.6%)
-$96.29M(+6.0%)
Dec 2006
-$102.44M(-169.4%)
-$16.89M(+50.4%)
-$102.44M(+8.1%)
Sep 2006
-
-$34.02M(-11.7%)
-$111.44M(-232.8%)
Jun 2006
-
-$30.46M(-44.6%)
-$33.48M(-5.9%)
Mar 2006
-
-$21.07M(+18.6%)
-$31.61M(+16.9%)
Dec 2005
-$38.03M(+75.2%)
-$25.88M(-158.9%)
-$38.03M(+18.7%)
Sep 2005
-
$43.93M(+253.7%)
-$46.80M(+55.3%)
Jun 2005
-
-$28.59M(-4.0%)
-$104.73M(+19.8%)
Mar 2005
-
-$27.49M(+20.7%)
-$130.66M(+14.7%)
Dec 2004
-$153.13M(-1050.4%)
-$34.65M(-147.4%)
-$153.13M(-11.3%)
Sep 2004
-
-$14.01M(+74.3%)
-$137.56M(+2.3%)
Jun 2004
-
-$54.51M(-9.1%)
-$140.83M(-12.8%)
Mar 2004
-
-$49.97M(-161.9%)
-$124.86M(-838.1%)
Dec 2003
-$13.31M(+84.3%)
-$19.08M(-10.4%)
-$13.31M(+53.0%)
Sep 2003
-
-$17.27M(+55.2%)
-$28.33M(-3.8%)
Jun 2003
-
-$38.54M(-162.6%)
-$27.28M(-157.5%)
Mar 2003
-
$61.58M(+280.6%)
-$10.60M(+87.5%)
Dec 2002
-$84.67M(-229.9%)
-$34.09M(-110.1%)
-$84.67M(-66.6%)
Sep 2002
-
-$16.23M(+25.7%)
-$50.83M(-36.8%)
Jun 2002
-
-$21.86M(-75.1%)
-$37.15M(-28.0%)
Mar 2002
-
-$12.48M(-4796.1%)
-$29.03M(-13.1%)
Dec 2001
-$25.66M(-21.7%)
-$255.00K(+90.0%)
-$25.66M(+19.8%)
Sep 2001
-
-$2.55M(+81.4%)
-$31.98M(-0.3%)
Jun 2001
-
-$13.74M(-50.8%)
-$31.88M(-15.1%)
Mar 2001
-
-$9.12M(-38.7%)
-$27.69M(-31.3%)
Dec 2000
-$21.09M(-70.0%)
-$6.57M(-168.4%)
-$21.09M(-69.8%)
Sep 2000
-
-$2.45M(+74.4%)
-$12.42M(+15.7%)
Jun 2000
-
-$9.55M(-280.0%)
-$14.72M(-43.9%)
Mar 2000
-
-$2.51M(-220.0%)
-$10.24M(+16.9%)
Dec 1999
-$12.40M(+13.9%)
$2.10M(+144.0%)
-$12.32M(+30.8%)
Sep 1999
-
-$4.76M(+6.0%)
-$17.80M(-21.6%)
Jun 1999
-
-$5.06M(-10.2%)
-$14.64M(-13.1%)
Mar 1999
-
-$4.59M(-35.6%)
-$12.95M(+10.4%)
Dec 1998
-$14.40M(-413.0%)
-$3.39M(-111.8%)
-$14.45M(-164.6%)
Sep 1998
-
-$1.60M(+52.5%)
-$5.46M(-508.2%)
Jun 1998
-
-$3.37M(+44.8%)
$1.34M(+139.4%)
Mar 1998
-
-$6.10M(-208.9%)
-$3.40M(-173.8%)
Dec 1997
$4.60M(+4.5%)
$5.60M(+7.7%)
$4.60M(-45.9%)
Sep 1997
-
$5.20M(+164.2%)
$8.50M(+431.3%)
Jun 1997
-
-$8.10M(-526.3%)
$1.60M(-82.6%)
Mar 1997
-
$1.90M(-80.0%)
$9.20M(+109.1%)
Dec 1996
$4.40M
$9.50M(+658.8%)
$4.40M(+186.3%)
Sep 1996
-
-$1.70M(-240.0%)
-$5.10M(-50.0%)
Jun 1996
-
-$500.00K(+82.8%)
-$3.40M(-17.2%)
Mar 1996
-
-$2.90M
-$2.90M

FAQ

  • What is Neurocrine Biosciences, Inc. annual free cash flow?
  • What is the all-time high annual free cash flow for Neurocrine Biosciences, Inc.?
  • What is Neurocrine Biosciences, Inc. annual free cash flow year-on-year change?
  • What is Neurocrine Biosciences, Inc. quarterly free cash flow?
  • What is the all-time high quarterly free cash flow for Neurocrine Biosciences, Inc.?
  • What is Neurocrine Biosciences, Inc. quarterly free cash flow year-on-year change?
  • What is Neurocrine Biosciences, Inc. TTM free cash flow?
  • What is the all-time high TTM free cash flow for Neurocrine Biosciences, Inc.?
  • What is Neurocrine Biosciences, Inc. TTM free cash flow year-on-year change?

What is Neurocrine Biosciences, Inc. annual free cash flow?

The current annual free cash flow of NBIX is $557.20M

What is the all-time high annual free cash flow for Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. all-time high annual free cash flow is $557.20M

What is Neurocrine Biosciences, Inc. annual free cash flow year-on-year change?

Over the past year, NBIX annual free cash flow has changed by +$195.60M (+54.09%)

What is Neurocrine Biosciences, Inc. quarterly free cash flow?

The current quarterly free cash flow of NBIX is $214.30M

What is the all-time high quarterly free cash flow for Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. all-time high quarterly free cash flow is $235.20M

What is Neurocrine Biosciences, Inc. quarterly free cash flow year-on-year change?

Over the past year, NBIX quarterly free cash flow has changed by +$64.40M (+42.96%)

What is Neurocrine Biosciences, Inc. TTM free cash flow?

The current TTM free cash flow of NBIX is $593.10M

What is the all-time high TTM free cash flow for Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. all-time high TTM free cash flow is $614.40M

What is Neurocrine Biosciences, Inc. TTM free cash flow year-on-year change?

Over the past year, NBIX TTM free cash flow has changed by +$153.00M (+34.76%)
On this page